Digitalis Ventures

Gallant Pet, Inc. is a pet service company based in San Diego, California, that specializes in stem cell preservation services for dogs. Founded in 2018, the company collects and banks stem cells from tissue during routine spay or neuter procedures. Gallant Pet also provides a platelet-rich plasma (PRP) kit for dogs suffering from osteoarthritis and other musculoskeletal issues. In addition to its preservation services, the company is engaged in clinical research to develop effective stem cell therapies for various conditions. Through its innovative approach, Gallant Pet enables pet owners to preserve their pets' young stem cells for future medical treatments.

Gallant Therapeutics is an animal health biotechnology company developing allogeneic, "off-the-shelf" stem cell therapies from their stem cell platform. Gallant is also the leading provider of non-invasive stem cell banking during the spay or neuter process, opening the door to novel regenerative medical treatments formerly unavailable for non-human family members. Clinical studies demonstrate stem cell therapies help pets with a multitude of ailments, including osteoarthritis, atopic dermatitis, chronic kidney disease, and chronic stomatitis, among others. Gallant's first product helps to save cats that would die of chronic gingivostomatitis, with a robust pipeline in development for companion animals.

Companion creates technology that simplifies how owners interact with and train their dogs. Companion's proprietary technology communicates with dogs through audio, and 3D sensing systems detect and analyze the dog's movement and behaviors. With machine learning, it can adapt in real-time, calculating the best way to engage with a dog. Companion rewards the dog for desired behaviors such as sit, down, stay, and recall using positive reinforcement techniques and proprietary data and algorithms.

Scout Bio, Inc. is a biotechnology company focused on developing innovative therapies for chronic health conditions in pets, utilizing veterinary biotechnology and gene therapy. Founded in 2016 and based in Philadelphia, Pennsylvania, the company specializes in creating one-time treatments to address significant issues such as anemia linked to chronic kidney disease in cats. Scout Bio employs Adeno-associated viral vector technology to design and deliver protein and monoclonal antibody therapeutics through single intra-muscular injections. The company's mission is to apply advancements from human medicine to improve veterinary care and enhance the quality of life for pets.

PetMedix Ltd is a veterinary biopharmaceutical company based in Cambridge, United Kingdom, focused on developing therapeutic antibody drugs for pets. Founded in 2017, the company utilizes advanced scientific methods to create innovative therapies that enhance the health and well-being of companion animals. PetMedix offers specialized platforms, including the Ky9 and Felyne transgenic mouse systems, which are designed to produce high-quality, therapeutic antibodies tailored specifically for pets. By leveraging over thirty years of expertise in drug development, PetMedix aims to provide effective medical solutions that meet the unique needs of animals, ensuring they receive appropriate care and treatment.

AnimalBiome specializes in personalized nutrition services focused on enhancing the gut health of dogs and cats through the science of the microbiome. The company offers microbiome tests that analyze the gut microbiome of individual pets, providing tailored nutrition recommendations based on the results. Additionally, AnimalBiome produces restorative supplements designed to introduce beneficial microbes sourced from healthy pets, helping to address microbiome imbalances. Through advanced diagnostics, including DNA sequencing, the company enables pet owners to gain insights into their pets' gut health, ultimately promoting a healthier and happier life for their animals.

Rejuvenate Bio Inc is a biotechnology company based in Brookline, Massachusetts, founded in 2017. The company focuses on developing gene therapies aimed at increasing the health and lifespan of domesticated animals, particularly dogs. Its innovative therapies utilize new DNA instructions to provide anti-aging treatments and address specific diseases in pets. The foundation of Rejuvenate Bio's research is rooted in work from the Wyss Institute at Harvard Medical School, and the company has established a gene therapy pipeline that targets chronic age-related diseases. By leveraging clinically validated gene targets and effective delivery methods, Rejuvenate Bio aims for long-lasting and well-tolerated gene expression, ultimately enhancing the quality of life for both animals and potentially humans facing chronic health challenges.

Smalls is a direct-to-consumer pet food company that specializes in producing human-grade and fresh food for cats. Founded in 2017 by co-founders Matt Michaelson and Calvin Hughes, the company is headquartered in New York, New York. Smalls offers a range of cat food options, including chicken, beef, freeze-dried chicken, and turkey and duck, all prepared with high-quality ingredients. The food is made from fresh meat and a small amount of green vegetables, gently cooked to preserve nutrients and moisture. Additionally, Smalls provides customized meal kits tailored to meet the specific nutritional needs of each cat, allowing pet owners to conveniently receive healthy and fresh food delivered directly to their homes.

Pawp, Inc. is a digital health clinic and telehealth platform focused on pet care, connecting pet owners with licensed veterinary professionals. Founded in 2020 and based in New York, the platform offers users unlimited 24/7 access to veterinarians, allowing for timely consultations that can often replace unnecessary in-person visits. Additionally, Pawp provides a yearly pet emergency fund of $3,000, serving as a financial safety net for unexpected veterinary expenses. By facilitating these services, Pawp aims to empower pet owners to make informed health decisions for their pets while managing costs effectively.

Scout Bio, Inc. is a biotechnology company focused on developing innovative therapies for chronic health conditions in pets, utilizing veterinary biotechnology and gene therapy. Founded in 2016 and based in Philadelphia, Pennsylvania, the company specializes in creating one-time treatments to address significant issues such as anemia linked to chronic kidney disease in cats. Scout Bio employs Adeno-associated viral vector technology to design and deliver protein and monoclonal antibody therapeutics through single intra-muscular injections. The company's mission is to apply advancements from human medicine to improve veterinary care and enhance the quality of life for pets.

PetMedix Ltd is a veterinary biopharmaceutical company based in Cambridge, United Kingdom, focused on developing therapeutic antibody drugs for pets. Founded in 2017, the company utilizes advanced scientific methods to create innovative therapies that enhance the health and well-being of companion animals. PetMedix offers specialized platforms, including the Ky9 and Felyne transgenic mouse systems, which are designed to produce high-quality, therapeutic antibodies tailored specifically for pets. By leveraging over thirty years of expertise in drug development, PetMedix aims to provide effective medical solutions that meet the unique needs of animals, ensuring they receive appropriate care and treatment.

MollyBox is a subscription-based e-commerce platform that caters to pet owners, specifically focusing on cats. Founded in 2015 by Yifu Sun and Yi Ju, the company is headquartered in Shanghai, China. MollyBox provides a monthly themed box that includes a selection of natural cat food and toys, allowing customers to conveniently receive these products on a regular basis. In addition to subscription options, customers can also purchase individual items, enhancing the accessibility of their offerings. Through this model, MollyBox aims to meet the needs of pet owners by delivering quality products directly to their homes.

Rejuvenate Bio Inc is a biotechnology company based in Brookline, Massachusetts, founded in 2017. The company focuses on developing gene therapies aimed at increasing the health and lifespan of domesticated animals, particularly dogs. Its innovative therapies utilize new DNA instructions to provide anti-aging treatments and address specific diseases in pets. The foundation of Rejuvenate Bio's research is rooted in work from the Wyss Institute at Harvard Medical School, and the company has established a gene therapy pipeline that targets chronic age-related diseases. By leveraging clinically validated gene targets and effective delivery methods, Rejuvenate Bio aims for long-lasting and well-tolerated gene expression, ultimately enhancing the quality of life for both animals and potentially humans facing chronic health challenges.